Cargando…

Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models

BACKGROUND: Severe radiation-induced lymphopenia (RIL) in patients undergoing chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is associated with decreased immunotherapy efficacy and survival. At The Christie and MD Anderson Cancer Center (MDACC), prediction models for lymphopenia were...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rossum, Peter S. N., Juan-Cruz, Celia, Stam, Barbara, Rossi, Maddalena M. G., Lin, Steven H., Abravan, Azadeh, Belderbos, José S. A., Sonke, Jan-Jakob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665840/ https://www.ncbi.nlm.nih.gov/pubmed/38023221 http://dx.doi.org/10.3389/fonc.2023.1278723

Ejemplares similares

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
por: Liu, FangJie, et al.
Publicado: (2022)

Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: A post hoc analysis of a randomized controlled trial
por: Ni, Wenjie, et al.
Publicado: (2022)

Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
por: Abravan, Azadeh, et al.
Publicado: (2020)

Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic
por: Iorio, Giuseppe Carlo, et al.
Publicado: (2020)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer
por: Kang, Byung-Hee, et al.
Publicado: (2022)

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial
por: He, Shasha, et al.
Publicado: (2022)

Prognosis and Risk Factors of Radiation-Induced Lymphopenia in Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy
por: Zhao, Qianqian, et al.
Publicado: (2020)

Multi-Organ Omics-Based Prediction for Adaptive Radiation Therapy Eligibility in Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy
por: Lam, Sai-Kit, et al.
Publicado: (2022)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
por: Liu, Haonan, et al.
Publicado: (2022)

Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer
por: Chitapanarux, Imjai, et al.
Publicado: (2013)

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques
por: Kim, Tae Hyung, et al.
Publicado: (2021)

Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer
por: Chen, Fang, et al.
Publicado: (2022)

Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction
por: Tian, Yuan, et al.
Publicado: (2021)

High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
por: Sun, Xin, et al.
Publicado: (2020)

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jianing, et al.
Publicado: (2021)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

CT-based dosiomics and radiomics model predicts radiation-induced lymphopenia in nasopharyngeal carcinoma patients
por: Huang, Qingfang, et al.
Publicado: (2023)

Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
por: Deck, Jared, et al.
Publicado: (2023)

Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer
por: Newman, Neil B., et al.
Publicado: (2020)

Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021)

Nomograms Predicting Survival of Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy Based on the 2018 FIGO Staging System
por: Meng, Qingyu, et al.
Publicado: (2022)

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma
por: d’Engremont, Christelle, et al.
Publicado: (2021)

Analysis of Treatment Outcomes and Prognosis After Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
por: Peng, Qing-he, et al.
Publicado: (2022)

Lymphopenia in Esophageal Cancer: What Have We Learned?
por: Wang, Jia-Lin, et al.
Publicado: (2021)

Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma
por: Li, Ji-Bin, et al.
Publicado: (2020)

A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
por: Xu, Yao-Can, et al.
Publicado: (2022)

Tumor regression patterns by follow-up duration in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy
por: Kong, Moonkyoo, et al.
Publicado: (2017)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Wang, Lili, et al.
Publicado: (2023)

RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy
por: Ming, Cheng, et al.
Publicado: (2023)

Outcomes of “sandwich” chemoradiotherapy compared with chemotherapy alone for the adjuvant treatment of FIGO stage III endometrial cancer
por: Wang, Shao-Jing, et al.
Publicado: (2022)

Measurement of Cervical Regression and Optimizing Brachytherapy Schedule Concurrently with External Beam Radiation Therapy in Cervical Carcinoma
por: Vedasoundaram, Parthasarathy, et al.
Publicado: (2019)

Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors
por: Fujiwara, Masateru, et al.
Publicado: (2015)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l2lfkt5a8qo80hsa7uiq6pa46g